Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling.

Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa). The antagonistic drugs, which suppress the activity of AR, are widely used in the treatment of PCa. However, the molecular mechanism of antagonism about how ligands affect the structures of AR remains elusive. To better understand the conformational variability of ARs bound with agonists or antagonists, we performed long time unbiased molecular dynamics (MD) simulations and enhanced sampling simulations for the ligand binding domain of AR (AR-LBD) in complex with various ligands. Based on the simulation results, we proposed an allosteric pathway linking ligands and helix 12 (H12) of AR-LBD, which involves the interactions among the ligands and the residues W741, H874, and I899. The interaction pathway provides an atomistic explanation of how ligands affect the structure of AR-LBD. A repositioning of H12 was observed, but it is facilitated by the C-terminal of H12, instead of by the loop between helix 11 (H11) and H12. The bias-exchange metadynamics simulations further demonstrated the above observations. More importantly, the free energy profiles constructed by the enhanced sampling simulations revealed the transition process between the antagonistic form and agonistic form of AR-LBD. Our results would be helpful for the design of more efficient antagonists of AR to combat PCa.

[1]  Massimiliano Bonomi,et al.  PLUMED 2: New feathers for an old bird , 2013, Comput. Phys. Commun..

[2]  Hualiang Jiang,et al.  Effects of HO-/MeO-PBDEs on androgen receptor: in vitro investigation and helix 12-involved MD simulation. , 2013, Environmental science & technology.

[3]  David W. Johnson,et al.  Molecular cell biology of androgen receptor signalling. , 2010, The international journal of biochemistry & cell biology.

[4]  R. Vessella,et al.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer. , 2012, Cancer research.

[5]  Isao Nakanishi,et al.  Subtle Structural Changes in Tetrahydroquinolines, A New Class of Nonsteroidal Selective Androgen Receptor Modulators, Induce Different Functions , 2012, J. Chem. Inf. Model..

[6]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  D. Tindall,et al.  Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.

[8]  D. Osguthorpe,et al.  Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. , 2011, Biochemistry.

[9]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[10]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[11]  Duncan Poole,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born , 2012, Journal of chemical theory and computation.

[12]  Jinming Zhou,et al.  Study of the impact of the T877A mutation on ligand‐induced helix‐12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens , 2010, Proteins.

[13]  R. Fletterick,et al.  The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.

[14]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[15]  H. Gronemeyer,et al.  Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain* , 1999, The Journal of Biological Chemistry.

[16]  J. P. Grossman,et al.  Biomolecular simulation: a computational microscope for molecular biology. , 2012, Annual review of biophysics.

[17]  J. Persson,et al.  Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer , 2013, Drug design, development and therapy.

[18]  Ross C. Walker,et al.  An overview of the Amber biomolecular simulation package , 2013 .

[19]  S Gnanakaran,et al.  Peptide folding simulations. , 2003, Current opinion in structural biology.

[20]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[21]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[22]  R. Dyer,et al.  Fast events in protein folding: helix melting and formation in a small peptide. , 1996, Biochemistry.

[23]  Raj Kumar,et al.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. , 2012, Endocrine reviews.

[24]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[25]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Laio,et al.  A bias-exchange approach to protein folding. , 2007, The journal of physical chemistry. B.

[27]  Jonathan Greer,et al.  The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.

[28]  Barry R. Goldspiel,et al.  Flutamide: An Antiandrogen for Advanced Prostate Cancer , 1990, DICP : the annals of pharmacotherapy.

[29]  R. Swendsen,et al.  THE weighted histogram analysis method for free‐energy calculations on biomolecules. I. The method , 1992 .

[30]  A. Laio,et al.  Escaping free-energy minima , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[32]  R. Fletterick,et al.  A conserved surface on the ligand binding domain of nuclear receptors for allosteric control , 2012, Molecular and Cellular Endocrinology.

[33]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[34]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[35]  Duane D. Miller,et al.  Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor* , 2005, Journal of Biological Chemistry.

[36]  Solène Grosdidier,et al.  Allosteric conversation in the androgen receptor ligand-binding domain surfaces. , 2012, Molecular endocrinology.

[37]  Woody Sherman,et al.  Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols. , 2012, The journal of physical chemistry. B.

[38]  Kenneth J. Pienta,et al.  Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.

[39]  Alessandro Laio,et al.  A Kinetic Model of Trp-Cage Folding from Multiple Biased Molecular Dynamics Simulations , 2009, PLoS Comput. Biol..

[40]  J. Bono,et al.  Novel drugs targeting the androgen receptor pathway in prostate cancer , 2014, Cancer and Metastasis Reviews.

[41]  V. Arora,et al.  Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.

[42]  Xue Xu,et al.  Dynamic communication between androgen and coactivator: Mutually induced conformational perturbations in androgen receptor ligand‐binding domain , 2011, Proteins.

[43]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[44]  B. Brooks,et al.  Langevin dynamics of peptides: The frictional dependence of isomerization rates of N‐acetylalanyl‐N′‐methylamide , 1992, Biopolymers.

[45]  Claudio N. Cavasotto,et al.  Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations. , 2008, Journal of molecular graphics & modelling.

[46]  Alessandro Laio,et al.  METAGUI. A VMD interface for analyzing metadynamics and molecular dynamics simulations , 2012, Comput. Phys. Commun..

[47]  Howard C. Shen,et al.  Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor , 2008, Molecular Cancer Therapeutics.

[48]  N. McCarthy Prostate cancer: Studying the classics , 2011, Nature Reviews Cancer.

[49]  Alessandro Laio,et al.  A VMD interface for analyzing metadynamics and molecular dynamics simulations ✩ , 2011 .

[50]  Takahiro Matsumoto,et al.  The androgen receptor in health and disease. , 2013, Annual review of physiology.

[51]  H. Xu,et al.  Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.

[52]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[53]  E. Wilson,et al.  Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone* , 2007, Journal of Biological Chemistry.

[54]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[55]  G. Blackledge,et al.  Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. , 1997, European Urology.

[56]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[57]  Ruben Abagyan,et al.  Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles , 2010, J. Comput. Aided Mol. Des..

[58]  C. Ryan,et al.  Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer , 2012, Current Treatment Options in Oncology.

[59]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.